Table 2 Comparison of outcomes of reported cohorts after stopping BRAF inhibitors.
From: Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
Case series reporting outcomes after discontinuation of BRAFi | Number of patients (CR) | Median duration of BRAFi treatment (months) | Therapy ceased due to toxicity | Median follow up after treatment cessation (months) | Relapse rate (%) | Median time to relapse (months) | Percentage rechallenged that responded (CR/PR) |
|---|---|---|---|---|---|---|---|
Wyluda et al.21 | 3 | 9–12 | 100% | 15 | 0 | N/A | N/A |
Tolk24 | 12 | 13 | 54% | 17 | 46% | 3 | 50% |
Carlino22 | 12 | N/A | 100% | 16 | 50% | 6.6 | 33% |
Vanhaecke25 | 16 | 21 | 63% | 12 | 53% | 2.5 | 63% |
Desvignes23 | 6 | 10 | 100% | 15 | 100% | 4 | 17% |
Warburton | 13 | 39 | 0 | 19 | 23% | 5 | 100% |
